QuellTX
Holly Newton, PhD, is an accomplished professional with extensive experience in program management and operations within the biopharmaceutical sector. Currently serving as Associate Director Program Manager Operations at Quell Therapeutics since February 2025, Holly previously held the position of Associate Director, Patient Supply Operations at Achilles Therapeutics plc, where responsibilities included leading cross-functional programs and driving strategic initiatives. Prior to that, Holly worked as a Consultant at Boston Consulting Group, delivering projects across healthcare and social impact sectors, and gained research experience as a PhD student at Imperial College London, culminating in first-author publication and multiple awards. Additionally, Holly co-founded Cambridge SciSearch and holds degrees from Imperial College London and the University of Cambridge in Biomedical Sciences and Natural Sciences, respectively.
This person is not in any teams
This person is not in any offices
QuellTX
4 followers
Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions.Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cellengineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.